http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111233821-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D323-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D323-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111233821-B |
| titleOfInvention | Neoantimycin derivatives containing 3-hydroxybenzoic acid group and its preparation method and application |
| abstract | The invention relates to the technical field of medicinal chemistry, in particular to a novel antimycin derivative with a new structure containing a 3-hydroxybenzoic acid group produced by fermentation of Streptomyces S. application. The molecular structure of neoantimycin generally contains 3-N-formamidosalicylic acid group, and the corresponding position of the molecular structure of UAT-B-E of the present invention is 3-hydroxybenzoic acid group. Anti-tumor cell tests found that the inhibitory activity of UAT‑B～E on human lung cancer cells, colorectal cancer cells and melanoma cells is equivalent to that of the control drug Cisplatin, and has weak toxicity to non-cancer cell lines. Therefore, UAT‑B～E is expected to be developed as a tumor Inhibitor. |
| priorityDate | 2020-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.